英文药名：ZACRAS Combination Tablets LD/HD（Azilsartan/Amlodipine Besilate） 中文药名：阿齐沙坦苯磺酸氨氯地平复方片 日文药名：ザクラス配合錠 生产厂家：武田药品 治疗类别名称 可持续发展AT1受体阻滞剂/持续钙拮抗剂配方 有效成分量： LD  阿齐沙坦20mg  苯磺酸氨氯地平2.5mg/片 HD  阿齐沙坦20mg  苯磺酸氨氯地平5mg/片 适用症：高血压 用法与用量 成年人：每日一次，每次服1片剂口服给药。这种药物是不是要用作一线治疗高血压的治疗。 药效药理 1. 作用机序 阿齐沙坦拮抗血管紧张素II结合于血管紧张素II类型1（AT1）受体，表示降血压作用由于由抑制主要是它的强有力的血管收缩作用在周围血管阻力的降低。 苯磺酸氨氯地平显示为二氢吡啶类钙拮抗剂的作用，但有一个特点，作用的开始是慢慢执着。 二氢吡啶类钙拮抗剂特异性地结合到膜的电压依赖性L-型钙通道，通过降低钙流入细胞，放松冠状或周围血管的平滑肌。 2.肾素 - 血管紧张素系统的影响 当在阿齐沙坦为20mg给药于健康成年人（12名患者），每天1次持续7天，血浆肾素活性，增加血浆血管紧张素I浓度和血管紧张素II浓度进行了观察。 包装规格： 配合錠LD： 100錠（10錠×10）、140錠（14錠×10）、500錠（バラ、10錠×50）、700錠（14錠×50） 配合錠HD： 100錠（10錠×10）、140錠（14錠×10）、500錠（バラ、10錠×50）、700錠（14錠×50） 生产厂家：武田药品 Zacras® Combination Tablets LD and Zacras® Combination Tablets HD, Fixed-Dose Combination of Azilsartan and Amlodipine, and Azilva® Tablets 10mg, Treatment for Hypertension, are Now Available in Japan Osaka, Japan, June 18, 2014— Takeda Pharmaceutical Company Limited (“Takeda”) announced today that Zacras® combination tablets, a fixed-dose combination ("FDC") of azilsartan (generic name) and amlodipine besylate hydrochloride (generic name, "amlodipine"), and Azilva® tablets 10mg (generic name: azilsartan) are now available for treatment of hypertension in Japan. Zacras is a tablet administrated orally once daily and has two dosage strengths, “Zacras® Combination Tablets LD” and “Zacras® Combination Tablets HD” which contain 20mg azilsartan/2.5mg amlodipine, and 20mg azilsartan / 5mg amlodipine respectively. Azilva tablets 10 mg is the addition of a new dosage strength to already-marketed Azilva Tablets 20mg and 40mg. Discovered by Takeda, azilsartan is a potent and lasting angiotensin II receptor blocker ("ARB") that lowers blood pressure by inhibiting the action of angiotensin II, a vasopressor hormone. Amlodipine is a calcium channel blocker ("CCB") having a hypotensive action by blocking inward calcium ion channels mainly in vascular smooth-muscle cells, resulting in peripheral arteriolar vasodilation. In a phase 3 clinical trial, the anti-hypertensive effect in diastolic blood pressure in the sitting position as the primary endpoint, of Zacras was statistically significant compared to monotherapy with either azilsartan or amlodipine. The ARB-CCB combination is one of the recommended treatments regimens as a combination therapy for the hypertension in the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2014), issued by the Japanese Society of Hypertension, from the standpoint of safety and efficacy. Simpler prescription using the FDC will improve adherence*, leading to improved blood pressure control. Furthermore, the NHI Prices of the FDC are set lower than the sum of the two individual drugs. This may positively impact healthcare costs. ”The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2014) report that there are approximately 43 million hypertensive patients in Japan, and of all individuals on anti-hypertensive medication, only approximately 30% of men and 40% of women have achieved their target blood pressure levels. We believe that Zacras, having strong and persistent hypotensive effects, may offer a new treatment option," said Masato Iwasaki, Ph.D., Director and Senior Vice President, Pharmaceutical Marketing Division of Takeda. "With our anti-hypertensive medications including this wider range of the azilsartan family, Takeda will continue contributing to the treatment of the disease by proposing optimal treatment options that fit the clinical conditions of individual patients.” Patients actively participate in the decision-making of treatment courses or policies, and the treatment is implemented and continued accordingly. Systolic blood pressure is under 140mmHg and diastolic blood pressure is under 90mmHg. References About Zacras® Combination Tablets Japanese Brand Name Zacras® Combination Tablets LD and Zacras® Combination Tablets HD Generic Name Azilsartan / Amlodipine besylate hydrochloride Dosage and Administration For adults, a tablet, 20mg azilsartan / 2.5mg amlodipine, or 20mg azilsartan / 5mg amlodipine, is orally administered once a day. It is not able to be used for the first line treatment of hypertension. Indication Hypertension NHI Price Zacras® Combination Tablets LD Zacras® Combination Tablets HD 武田在日本推出高血压药物Zacras复方片和Azilva片 2014年6月19日，高血压药物在日本推出Zacras复方片和Azilva片（azilsartan，阿齐沙坦，10mg）。Zacras复方片是阿齐沙坦（azilsartan）和氨氯地平（amlodipine）固定剂量组合（FDC）复方药，该药为每日一次的口服片剂，有2种剂量：Zacras复方片LD（azilsartan/amlodipine，20mg/2.5mg）和Zacras复方片HD（20mg/5mg）。Azilva（10mg）提供了一种新的剂量强度，目前已上市的剂量为Azilva（20mg）和Azilva（40mg）。 阿齐沙坦（zilsartan）是一种血管紧张素II受体阻滞剂（ARB），通过阻断血管升压激素血管紧张素II发挥降血压作用；氨氯地平（amlodipine）是一种钙通道阻滞剂（CCB），通过抑制血管平滑肌细胞内向钙通道发挥降血压作用，导致外周动脉血管舒张 http://www.info.pmda.go.jp/go/pack/2149121F1021_1_06/